The first-in-human study of Ossium’s bone marrow (PRESERVE I) was recently featured in an article published by Healio, a major medical news source for healthcare professionals. The article includes an interview with Kevin Caldwell, CEO, Co-Founder & President of Ossium Health, and Erin Leckrone, Vice President of Clinical Trials at the National Marrow Donor Program (NMDP)/Be The Match. In the interview, Caldwell and Leckrone outline the goals of the Ossium-NMDP/Be The Match partnership, including how the organizations plan to work together to fill unmet needs in hematopoietic cell transplantation. “We are dedicated to partnering with organizations like Ossium, who have innovative products that could potentially fill the unmet needs in transplantation,” said Leckrone. Leckrone goes on to explain how the clinical study data will be leveraged to drive the integration of Ossium’s bone marrow into the NMDP/Be The Match registry, facilitating seamless access for transplant centers in the future. 

Read the full article and interview here.